Morgan Stanley Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $32
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $32.
Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $32.